Prognostic value of circulating tumor DNA and copy-number alterations in patients receiving tandem [225Ac]Ac-/[177Lu]Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer: a prospective observational study.

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) - Novartis

http://www.ncbi.nlm.nih.gov/pubmed/42681619

Alfred Morgenstern; Clemens Kratochwil; Frank Bruchertseifer; Hendrik Rathke; Hilal Özgür; Mareike Roscher; Mariam Amghar; Martina Benešová-Schäfer; Thomas Hielscher; Tobias Rausch; Ulrike Bauder-Wüst; Vladimír Beneš

Sep 3, 2026